The U.S. pharmaceutical sterility testing market size is expected to reach USD 713.6 million by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 11.3% over the forecast period. Supportive government investment in healthcare industry, increasing R&D activities, and drug launches are the key factors driving market growth.
The
government is keen on bringing down healthcare costs which is anticipated to
encourage the U.S. Food and Drug Administration (FDA) to promote fast approvals
of generic pharmaceuticals. Faster approvals drive the need for newer sterility
testing methods. This is anticipated to encourage market participants to spend
more on sterility solutions and in turn, expand the market. With increasing
demand for drugs, companies are launching newer drugs with different routes of
administration, dosage, and indication. These launches require thorough
sterility testing and thus, are anticipated to drive market growth.
On
the basis of type, the U.S. pharmaceutical sterility testing market is
segmented into in-house and outsourcing. Most market players prefer outsourcing
sterility testing services, as it is economically viable. Companies shortlist
and select outsourcing firms based on their experience, expertise, and quality
of service. Hence, it is difficult for new players to enter into this area.
Companies
active in the U.S. pharmaceutical sterility testing market are Charles River
Laboratories, Pace Analytical Series LLC, DynaLabs, Infinity, Boston
Analytical, and others. Market players employ various growth strategies such as
mergers, capacity expansion, and venturing into new regions. For instance, in
April 2018, Charles River Labs completed acquisition of MPI Research, a
non-clinical Contract Research Organization (CRO) providing detailed services to
medical device and biopharmaceutical companies. This acquisition is anticipated
to expand biotechnology client base of the former and to provide the company
access to MPI’s scientific expertise and quality services.
For more info visit here: https://www.grandviewresearch.com/industry-analysis/us-pharmaceutical-sterility-testing-market
U.S.
Pharmaceutical Sterility Testing Market Report Highlights
- U.S.
pharmaceutical sterility testing market was valued at USD 302.2 million in
2017 and is expected to grow lucratively over the forecast period
- In terms of
revenue, outsourcing segment is anticipated to grow at a lucrative rate
during the forecast period.
- Sterility
testing segment was valued at USD 97.6 million in 2016 and is anticipated
to witness swift growth over the forecast period.
Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/us-pharmaceutical-sterility-testing-market/request/rs1
U.S.
Pharmaceutical Sterility Testing Market Segmentation
Grand View Research has
segmented the U.S. pharmaceutical sterility testing market on the basis of
type, test type, end use, and sample:
U.S.
Pharmaceutical Sterility Testing by Type (Revenue, USD Million, 2014 - 2025)
- In-house
- Outsourced
U.S. Pharmaceutical
Sterility Testing by Test Type (Revenue, USD Million, 2014 - 2025)
- Sterility Test
- Bioburden Testing
- Bacterial Endotoxin Test
U.S.
Pharmaceutical Sterility Testing by End Use (Revenue, USD Million, 2014 - 2025)
- Compounding Pharmacies
- Medical Device Companies
- Pharmaceutical Companies
- Others
U.S.
Pharmaceutical Sterility Testing by Sample (Revenue, USD Million, 2014 - 2025)
- Sterility Drugs
- Medical Devices
- Biologics & Therapies
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment